Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 2 of 87 · 4158 articles
Reliable, low‑cost lab methods to measure mesalazine in tablets help ensure pharmaceutical quality and correct dosing of 5‑ASA drugs used in ulcerative colitis and IBD.
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a...
This study maps gene and microRNA changes linked to ulcerative colitis and tests how deleting STAT6 or treating mice with Corylus avellana extract shifts those molecular signatures. Identifying such molecular players may...
If baseline mucosal gene-expression patterns can identify patients more likely to achieve mucosal healing across drug classes, those patterns could eventually help personalize treatment selection or stratify patients in...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
This preclinical study describes a new cell‑based approach — macrophages engineered to secrete IL‑10 — that reduced inflammation and improved colon outcomes in a mouse colitis model, suggesting a potential avenue for...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from Inflammatory bowel diseases.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from BMJ case reports.
This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
The study asks whether hospitalized IBD patients have longer QT intervals—information that could affect assessment of arrhythmia risk or monitoring when prescribing QT-prolonging drugs.
A positive stool screening test requires diagnostic colonoscopy to check for colorectal cancer or other treatable conditions. Understanding why some people skip follow-up helps programs reduce missed diagnoses and...
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
If you or someone with MS is treated with rituximab (an anti‑CD20 drug), this study suggests a small increased risk of developing IBD—mostly Crohn’s disease—over time. That risk is rare but may affect treatment decisions...
The study suggests postbiotics from a gut bacterium can reduce inflammation in a mouse colitis model and identifies a candidate metabolite and signaling pathway that could be targeted in future IBD research.
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
Market shifts — including biosimilars, new biologics, and small-molecule drugs — can affect treatment availability, cost, and prescribing options for people with Crohn’s disease. News about acquisitions and product...
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Stem Cell Research & Therapy.
The trial evaluated an investigational, non-drug vagal nerve stimulation device as a potential therapy for ulcerative colitis in adolescents and young adults, which could expand treatment options beyond conventional...
The study aims to clarify differences in visceral sensitivity and collect multiple biological samples that could help explain why some people with IBD have IBS-like symptoms. Findings could inform better symptom-targeted...
Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with...
Cure8 could only read part of this source from bvmsports.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.
People with Crohn’s disease who have had, or will have, intestinal surgery may benefit from better tools to predict early complications and endoscopic recurrence. Predictive models could help tailor follow-up and...
This study links brain structure and function differences to clinical measures and neurotransmitter systems in Crohn’s disease, which may help explain cognitive, mood, or quality-of-life effects some people with CD...
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this...
The work helps explain why people with IBD often have unstable gut microbiomes and limited recovery of beneficial bacteria, linking those patterns to inflammation — which is relevant for efforts to develop...
The study identifies a botanical extract that reduced colitis severity in mice and pinpoints the PI3K/Akt/FOXO3A pathway as a possible mechanism — a potential starting point for new therapeutic research relevant to...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Cureus.
Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe...
This case highlights that full-thickness rectal prolapse in a toddler can be caused by very early-onset ulcerative colitis rather than isolated pediatric prolapse or allergy.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Vedolizumab, and Anti Integrin. The original article is from gastroendonews.com.
A patient describes recovering from severe Crohn’s-related malnutrition and living with an ileostomy, then regaining weight and muscle after reversal—topics many people with IBD face. The story highlights practical...
Personal stories can reduce isolation and show that people with Crohn’s disease—including high-level athletes—manage their condition and return to activities they care about. This can be encouraging and raise public...
IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Middle East journal of digestive...
If you have moderate-to-severe UC and are treated with adalimumab (or other therapies), this study suggests the rectum may be slower or less likely to reach endoscopic and histologic healing than more proximal colon...
The review evaluates a revised preprint linking GM-CSF, macrophages, and ILC-like cells in Crohn’s disease using human spatial transcriptomics and zebrafish experiments. It highlights limitations that matter because they...
Personal recovery stories can offer hope and practical ideas for people with Crohn’s who are dealing with malnutrition, body-image issues, ostomy surgery, or post-surgical recovery.
New mouse-model research identifies TIMD4-dependent macrophage pathways that influence monocyte recruitment and colitis severity and tests a TIMD4-derived peptide delivered in nanoparticles that reduced inflammation in...
Stories like this highlight how Crohn’s can be misattributed to stress—especially for women—and the emotional, educational, and physical toll of delayed diagnosis and prolonged flares. They can help others recognise...
These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...
This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Personal stories like this show how surgery, nutrition, and tailored exercise can help someone with Crohn’s rebuild strength, body weight, and confidence. They can offer practical ideas and emotional encouragement to...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Middle East journal of digestive diseases.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Ustekinumab, and IL-12/23 inhibitor. The original article is from Gastro hep advances.
